Advertise on podcast: VJOncology Podcast

On this week’s episode of VJOncology podcasts, we explore advances in personalized approaches towards prostate cancer. Join Anis Hamid of Memorial Sloan Kettering Cancer Center, New York, NY, Daniel Keizman of Ichilov-Sourasky Medical Center, Tel-Aviv, Israel, Susan Halabi of Duke Cancer Institute, Durham, NC, and Andrew Armstrong of Duke University Medical Center, Durham, NC, as they discuss predictors of benefit for intensified therapy in metastatic hormone sensitive prostate cancer, a circulating tumor DNA (ctDNA)-based prognostic model in metastatic castration-resistant prostate cancer, and the association between tumor genetics, smoking and prostate cancer outcomes.

In this week’s VJOncology podcast, we are joined by Philippe Spiess of Moffitt Cancer Center, Tampa, FL, to explore the role of tumor acidity in cancer progression and immune evasion. Dr Spiess discusses how the acidic tumor microenvironment suppresses T-cell function, the potential of pH modulation to enhance antitumor immunity and improve responses to immunotherapy, and preclinical findings on tumor growth and survival. He also outlines an upcoming first-in-human trial investigating transdermal delivery of a therapy designed to modulate tumor pH, including its rationale, key safety and efficacy biomarkers, and potential role in combination with existing immunotherapies.

For this week’s VJOncology podcast, we mark Breast Cancer Awareness Month by bringing you the key updates in breast cancer. Join leading experts Zunairah Shah of Roswell Park Comprehensive Cancer Center, Buffalo, NY, Walter Weber of University Hospital Basel, Basel, Switzerland, Claudio Vernieri of Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Yeon Hee Park of Samsung Medical Center, Seoul, South Korea, and Jennifer Ligibel of Dana-Farber Cancer Center, Boston, MA, as they discuss recent therapeutic and surgical advances. They explore data from the BWEL, PREPEC, DESTINY-Breast09, PALMARES-2, ASCENT-07 trials, as well as the link between GLP-1 receptor agonist therapy and breast cancer risk.

In this week’s VJOncology podcast, we mark Liver Cancer Awareness Month by exploring the latest advances in hepatocellular and hepatobiliary cancers. Join Ghassan Abou-Alfa of Memorial Sloan Kettering Cancer Center, New York, NY, Manon Allaire of Greater Paris University Hospitals, Paris, France, Stephen Lam Chan of The Chinese University of Hong Kong, Hong Kong, China, and Lorenza Rimassa of Humanitas University, Milan, Italy, as they discuss findings from the EMERALD-3 trial, challenges in selecting first-line therapies, the role of cirrhosis and artificial intelligence in patient management, evolving immunotherapy strategies, and emerging modalities including next-generation immune checkpoint inhibitors, antibody-drug conjugates, and cell therapies.

This week on VJOncology podcasts, we bring you a roundtable discussion from iwCAR-T 2026 exploring novel cellular therapy technologies in solid tumors. Join Marco Davila of Roswell Park Comprehensive Cancer Center, Kedar Kirtane of Moffitt Cancer Center, Nathan Welty of Penn Medicine, Eric Smith of Dana Farber Cancer Center, Sebastian Kobold of Ludwig Maximilian University, and Yihan Zuo of Roswell Park Comprehensive Cancer Center, as they explore novel engineering strategies and how to overcome common issues with CAR T-cell therapy in solid tumors.

In this week’s VJOncology podcast, we had the opportunity to attend the 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea, where we explored the latest advances across thoracic oncology. Join Tom Newsom-Davis of Chelsea and Westminster Hospital NHS Foundation Trust, London, UK, Giulia Pasello of Institute Oncology Veneto, Padua, Italy, Alexander Spira of Virginia Cancer Specialists and US Oncology, Fairfax, VA, Mark Jeng of Memorial Sloan Kettering Cancer Center, New York, NY, and Triparna Sen, Ohio State University, Columbus, OH, as they discuss the PAPILLON and REZILIENT 3 studies, perioperative treatment in mesothelioma, advances in small cell lung cancer, and more.

In this week’s VJOncology podcast, we explore the latest developments in neuro-oncology, including emerging approaches in immunotherapy, PARP inhibition, and radioligand therapy. Join Nicholas Blondin and Sylvia Kurz of Yale University School of Medicine, New Haven, CT, Martin Hojgaard of Rigshospitalet, Copenhagen, Denmark, Tolga Tuncer of the University of Kansas Medical Center, Kansas, KC, and Dinu Stefan of François Baclese Cancer Center, Caen, France, as they discuss key ASCO findings, including the MAGMA and ROADS trials, lutetium-177 dotatate in meningioma, the molecular landscape of MTAP deletions, neoantigen-specific T-cell therapy for glioblastoma, and intermittent olaparib combined with radiotherapy and temozolomide in high-grade gliomas.

In recognition of Gynecologic Cancer Awareness Month, this episode of VJOncology podcasts explores recent advances shaping the treatment and diagnosis of gynecologic cancer. Join leading experts Linda Mileshkin of Peter MacCallum Cancer Center, Melbourne, Australia, Martin Hojgaard of Rigshospitalet, Copenhagen, Denmark, Claudia Marchetti of Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy, and Shailendra Dandge of the Society for Health Allied Research Education India, Hyderabad, India, as they discuss key developments. They cover new data for novel therapeutics including puxitatug samrotecan and EIK1003, the prognostic effect of neoadjuvant chemotherapy in ovarian cancer and a community health volunteer-led intervention to improve cervical cancer screening participation in low-resource settings.

In this week’s VJOncology podcast, we explore recent advances in therapeutic radiopharmaceuticals for metastatic castration-resistant prostate cancer, including emerging alternatives to lutetium-177. Join Jeremie Calais of University of California, Los Angeles, CA, Pedro Barata of Seidman Cancer Center, Cleveland, OH, and Enrique Gallardo of Parc Taulí University Hospital, Barcelona, Spain, as they discuss actinium-225-based PSMA-targeted radioligand therapies, findings from the CONVERGE-01, AcTION, and ProstACT Global trials, the expanding PSMA-targeted treatment landscape, and final overall survival results from PEACE-3.

On this week’s episode of VJOncology podcasts, we bring you head and neck cancer highlights in immuno-oncology from the 2026 ASCO Annual Conference. Join Barbara Burtness from the Yale School of Medicine, Hannah Kenny from Thomas Jefferson University Hospital, Ari Rosenberg from the University of Chicago, Nabil Saba from Emory University, and Kedar Kirtane from Moffitt Cancer Center as they discuss highlights from the meeting. They explore new data from key trials including OrigAMI-4, EV-202 and KEYNOTE-412, as well as emerging cellular therapies and checkpoint inhibitors.

In this week’s VJOncology podcast, we explore the latest advances in skin cancer from ASCO 2025, with a focus on melanoma and emerging cellular therapies. Join Alexandra Haugh of Massachusetts General Hospital Cancer Center, Boston, MA, Kalijn Bol of Radboud University Medical Center, Nijmegen, Netherlands, Allison Betof Warner of Stanford University, Stanford, CA, Omid Hamid of The Angeles Clinic and Research Institute, Los Angeles, CA, and Peter Forsyth of Moffitt Cancer Center, Tampa, FL, as they discuss real-world outcomes with lifileucel, treatment sequencing in BRAF-mutated melanoma, emerging cellular therapies and vaccines, and preclinical approaches to CAR T-cell therapy for leptomeningeal disease.

Welcome to another episode of VJOncology Podcast, featuring a roundtable discussion from iwCAR-T 2026, which took place in Tampa, FL. This week, our experts explore advances in tumor-infiltrating lymphocyte (TIL) therapy for solid tumors. Join Benjamin Creelan from Moffitt Cancer Center, Rodabe Amaria from the University of Texas MD Anderson Cancer Center, Daniel Olson from the University of Chicago, and Lilit Karapetyan from Moffitt Cancer Center as they discuss sequencing, duration issues and armoring approaches for TIL therapy in melanoma and other solid tumors.

In this week’s VJOncology podcast, we explore the latest developments in artificial intelligence (AI) in oncology and their potential to transform cancer care. Join Eleonora Teplinsky, Valley Health System, Paramus, NJ, Gil Shamai, Technion–Israel Institute of Technology, Haifa, Israel, Matthew Kurian, St. Elizabeth Healthcare, Edgewood, KY, Jai Patel, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, and Marie Hanaoka, Institute of Science Tokyo, Japan, as they discuss AI-driven patient education, biomarker prediction, clinical decision-making, trial matching, and surgical training, alongside the opportunities and challenges of integrating artificial intelligence into oncology practice.

In this week’s VJOncology podcast, we present highlights in genitourinary cancer from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Join Andrew Armstrong of Duke University Medical Center, Srikala Sridhar of the Princess Margaret Cancer Centre, Tian Zhang of UT Southwestern Medical Center, and Lucia Nappi of the University of British Columbia as they discuss key data and clinical perspectives across prostate, bladder, kidney and testicular cancer, including the PROTEUS, CHAMP, TALAPRO-3, A-DREAM and SWOG S1823 trials, as well as the role of enfortumab vedotin and pembrolizumab in bladder cancer.

In this week’s VJOncology podcast, we had the opportunity to attend the 2026 ESMO Gastrointestinal Cancers Congress in Munich, Germany, where we explored the latest advances across gastrointestinal malignancies. Join Teresa Macarulla, Vall d’Hebron University Hospital, Barcelona, Spain, Giulia Martini, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy, Lorenza Rimassa, Hunimed University, Milan, Italy, Kohei Shitara, National Cancer Center Hospital East, Kashiwa, Japan, and Silvio Ken Garattini, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy, as they discuss emerging KRAS G12D-targeted therapies in pancreatic cancer, ctDNA-guided treatment strategies in metastatic colorectal cancer, novel targeted approaches for biliary tract cancer, HER2-directed therapies in gastroesophageal cancer, and evolving treatment paradigms in hepatocellular carcinoma and gastric cancer.